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Editorial

Transcatheter edge-to-edge repair of the mitral valve: A promising bridge to heart transplant for
select patients?

Despite the advancements in pharmacological and device therapies,
end-stage heart failure (HF) afflicts a significant proportion of HF pa
tients and mortality rates remain considerably high [1]. Heart transplant
remains the only curative therapy. Because of a limited pool of heart
donors and consequently a steady but finite rate of heart transplant,
there is a growing interest in alternative therapeutic options [2]. Left
ventricular assist devices (LVADs) are performed as a bridge to trans
plantation or as a destination therapy. However, LVADs have several
disadvantages, including cost and associated co-morbidities (e.g., driveline infection, bleeding, thromboembolic complications) [2].
Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve has
emerged as an alternative therapy for patients with moderate-severe and
severe secondary mitral regurgitation (MR) in the setting of heart failure
with reduced ejection fraction (HFrEF) and persistent symptoms re
fractory to maximally-tolerated medical therapy [3]. The 2020 Amer
ican College of Cardiology/American Heart Association valvular heart
disease guidelines provided a class IIa recommendation for TEER for
patients with symptomatic cardiomyopathy and chronic severe sec
ondary MR despite optimal guideline-directed medical therapy [4].
Concomitant severe MR is prevalent among patients with end-stage HF
[5]. A prior analysis of the MitraBridge registry including 119 patients
showed that TEER might be a feasible and safe bridge therapy in patients
with moderate-severe and severe MR and end-stage HF. Notably, none of
the patients died at 30-days. During a median of 532 days, 15% un
derwent elective transplant, 15% remained or could be included on the
transplant list, and 23.5% had no further indications for transplant due
to clinical improvement [6]. However, detailed data regarding the he
modynamic evaluation prior to and after TEER were lacking in that
study.
It is in this context that the current investigation should be viewed.
The investigators performed a retrospective observational analysis
evaluating the hemodynamic parameters before and after TEER among
patients with HFrEF and severe MR who otherwise could be considered
for heart transplantation [7]. The study included 17 patients recruited
between 2011 and 2019 and had repeat right heart catheterization
(RHC) at a mean of 5.9 months. TEER was successful (i.e., postprocedure MR ≤ 2+) in all patients, and the reduction of MR
remained stable in 88% at follow-up. TEER was associated with a
reduction in pulmonary vascular resistance (PVR) (3.5 ± 2.2 to 2.3 ± 1.2
wood units), systolic pulmonary artery pressure (55.4 ± 15 mmHg to
45.6 ± 9.8 mmHg), and transpulmonary gradient (12.0 ± 7.5 mmHg to
9.7 ± 5.3 mmHg). TEER was also associated with improved cardiac
output (3.7 ± 0.9 l/min to 4.6 ± 1.3 l/min) and New York Heart Asso
ciation (NYHA) functional class. In a subgroup of 5 patients with

elevated PVR > 3.5, TEER was also associated with a significant
reduction in PVR (6.1 at baseline to 2.9 wood units) and improvement in
cardiac output (3.3 at baseline to 4.4 l/min). Collectively, these findings
suggest that TEER might reduce PVR, which is known to be an important
hemodynamic parameter in patients being evaluated for heart trans
plant and considered part of the eligibility criteria for heart trans
plantation. Similar to the analysis from the MitraBridge registry [6], the
clinical outcomes of TEER in this study were reassuring. During a mean
of ~36 months, 3 patients underwent heart transplant, 4 patients
received LVAD, 1 patient was on the waiting list for heart transplant
while 10 patients were managed with guideline-directed medical ther
apy. Survival rate was 86% at 1 year and 71% at 3 years [7].
The findings from this study are indeed provocative and relevant.
The study suggests that TEER might reduce PVR and improve other
hemodynamic parameters among select patients with end-stage HF. But
some issues deserve further consideration. First, this is an observational
study that lacks a control group. Second, the study was conducted in a
single high-volume center. Hence, the findings might be subject to
referral bias, which would limit the generalizability. Third, the timing of
repeat RHC was not systematically planned, thus approximately half of
eligible patients did not undergo repeat RHC and were not included in
the analysis. Finally, the study spans over a long period (i.e., 8 years),
and recruited only a small number of patients. Notwithstanding these
issues, this study contributes to the literature supporting that TEER
might be a feasible and safe procedure among select end-stage HF pa
tients as a bridge to transplant.
TEER could be a potential “triage point” for patients with severe MR
and end-stage HF who are otherwise potentially eligible for heart
transplant, as a: bridge to transplant, bridge to candidacy for transplant
in patients with potentially reversible contraindications, or medical
management only if the symptoms improve after the procedure. How
ever, a knowledge gap still exists on which subset of patients with severe
MR and end-stage HF would benefit from TEER. In a secondary analysis
of the Multicenter Study of MagLev Technology in Patients Undergoing
Mechanical Circulatory Support Therapy with HeartMate 3 (MO
MENTUM 3) trial including 927 patients who received LVAD, LVAD was
associated with significant improvement in secondary MR within 1
month and this effect was sustained up to 2 years [8]. As such, patients
who do not meet the criteria of the MOMENTUM 3 trial might be can
didates for TEER. Noticeably, the patients in this study, as well as the
MitraBridge registry, were relatively younger and had a higher preva
lence of comorbidities including advanced renal disease [6,7],
compared with those enrolled in the pivotal TEER trials [9,10]. This is
an important consideration since some of these comorbidities are linked
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with worse outcomes after TEER. Incorporating a structural heart team
approach would be reasonable in evaluating these patients to determine
the appropriate therapeutic strategy.
The authors are to be commended on their efforts, which suggest that
TEER may be a promising bridge that can improve the eligibility of select
end-stage HF patients with severe MR for heart transplantation. The
findings from this study should encourage future larger studies with an
adequate control group before the widespread adoption of this
approach.
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